Moreover, both ferrostatin‐1 and liproxstatin‐1 repressed HFD‐induced upregulation of serum alanine transaminase, aspartate transaminase, gamma glutamyl transpeptidase, nonalcoholic fatty liver disease activity (NAS) score (Figure S1B), indicating their additional therapeutic potential in nonalcoholic fatty liver disease (NAFLD). The gene discussed is GGTLC1; the disease is neonatal abstinence syndrome.